Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer.
Instituto Valenciano de Oncologia, Valencia, Spain.
Nuria
N
Ruiz
Carlos
C
Fernandez-Martos
Ignacio
I
Romero
Angel
A
Pla
Joaquin
J
Maiquez
Ana
A
Calatrava
Vicente
V
Guillem
D000230:Adenocarcinoma / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005670:Fusarium / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000139:chemically induced*; D009300:Nasal Septum / Q000382:microbiology*; D009668:Nose Diseases / Q000382:microbiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab